Novartis to relocate Arnhem operations to Amsterdam, 400 jobs affected

pharmafile | September 19, 2018 | News story | Manufacturing and Production, Research and Development Netherlands, Novartis, amsterdam, pahrma, pharma 

Novartis has announced it is to relocate its operations in Arnhem in the Netherlands to the capital city of Amsterdam, according to Dutch regional public broadcaster Omroep Gelderland, uprooting the site from the base it has occupied since the 1950s.

It has been reported that the reason for the move was due to the high renovation costs of the current building on the Raapopseweg. Around 400 staff currently work at the Arnhem site and all will be affected by the move, with the expectation that they will transfer to the new base of operations.

The company said that the new destination was a “logical choice”, given its close proximity to many clients and suppliers around the capital. The move is scheduled for mid-2019 and coincides with the controversial move of the European Medicines Agency to the city of Amsterdam, following the UK’s decision to leave the European Union which forced the agency to vacate its current base in London.

Jan van Dellen,  Alderman for Economic Affairs and Sport in municipality of Arnhem, lamented the news, saying the departure of a company of Novartis’ stature is never good for the city, while Ron van Gent, Regional Director at Dutch employers’ federation VNO-NCW, remarked: “We regret it very much. Novartis is an important company and it involves a large number of high-quality jobs in the Health cluster of Arnhem-Nijmegen.”

Advertisement

Matt Fellows

Related Content

Pharma sees climate disruption as growing supply-chain risk

Nine in ten pharmaceutical companies across the UK and G7 countries expect climate-related disruption to …

AI in pharma: From lab development to patient impact

In the decade to 2025, AI use in vaccine development has increased markedly but is …

Scotland starts newborn screening for SMA

As part of a two-year evaluation funded by the Scottish government and Novartis, Scotland will …

The Gateway to Local Adoption Series

Latest content